ClinicalTrials.gg
CompletedNCT07851870Updated Oct 1, 2026

Spinal Morphine and Atropine Added to General Anaesthesia for Nausea and Pain After Abdominal Laparoscopy

A Phase 4 interventional study of Intrathecal bupivacaine, morphine and atropine and General anaesthesia in Postoperative Nausea and Vomiting, Postoperative Pain and Anesthesia, sponsored by Universitas Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Universitas Indonesia · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2026, registered Sep 2026).
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Laparoscopic abdominal surgery carries one of the highest risks of postoperative nausea and vomiting (PONV), and postoperative opioids given for pain are themselves emetogenic. Intrathecal morphine provides prolonged analgesia but increases nausea; intrathecal atropine 100 µg has been reported to reduce morphine-related nausea under spinal anaesthesia alone, but has not been tested within a combined spinal-general technique.

This randomised, open-label, parallel-group trial compared combined spinal-general anaesthesia (CSGA), hyperbaric bupivacaine 10 mg, morphine 100 µg and atropine 100 µg given intrathecally before induction, followed by general anaesthesia, with general anaesthesia (GA) alone in adults undergoing elective abdominal laparoscopy. Both groups received identical general anaesthesia, multimodal analgesia (paracetamol and ketorolac at skin closure), end-of-case ondansetron and neostigmine-atropine reversal.

The primary outcome was the occurrence of PONV within 24 hours after surgery. Secondary outcomes were postoperative pain, rescue antiemetic and rescue opioid requirements, intraoperative fentanyl consumption and perioperative haemodynamics.

Read the detailed description

summarise Methods: setting, randomisation by computer-generated sequence, spinal technique at L4-5 with 27-G Quincke needle, target T6 block, induction and maintenance regimen, assessment schedule at 1, 2, 6, 12 and 24 h, sample size assumptions of 75% vs 40% PONV at α 0.05 and 80% power, per-protocol analysis.

02

Conditions studied

  • Postoperative Nausea and Vomiting
  • Postoperative Pain
  • Anesthesia
  • Anesthesia Spinal
  • Laparoscopy

Keywords

  • Atropine
  • Intrathecal
  • Morphine
  • Spinal anaesthesia
  • PONV
  • Laparoscopy
  • Opioid sparing
03

In context

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

This study's enrollment of 63 is below the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.

Browse Postoperative Nausea and Vomiting studies →

Lead sponsor

Universitas Indonesia is the lead sponsor of 39 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 64 years
  • I or II
  • 30 kg/m² or less
  • Scheduled for elective digestive, gynaecological or urological laparoscopy
  • Written given

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled stage 2 hypertension
  • Heart failure, arrhythmia, valvular heart disease or atrioventricular block
  • Cerebrovascular event within the previous 3 months
  • Raised intracranial pressure
  • Severe renal or hepatic disease
  • Coagulopathy
  • Infection at the site of lumbar puncture
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Combined spinal-general anaesthesia (CSGA)

    Before induction, spinal anaesthesia at L4-5 in the sitting position with a 27-G Quincke needle: 0.5% hyperbaric bupivacaine 10 mg, preservative-free morphine 100 µg and atropine sulphate 100 µg, made up to 4 mL with 0.9% saline, targeting a T6 sensory level. General anaesthesia was then induced and maintained as in the comparator arm.

    Drug: Intrathecal bupivacaine, morphine and atropine · Procedure: General anaesthesia · Drug: Multimodal analgesia and antiemetic prophylaxis

  • Active comparator
    GA alone

    General anaesthesia without any neuraxial block: induction with lidocaine 1.5 mg/kg, fentanyl 2 µg/kg, propofol 2 mg/kg and rocuronium 0.6 mg/kg; maintenance with sevoflurane in oxygen-air at target MAC 0.8, with fentanyl 25-50 µg boluses for haemodynamic response.

    Procedure: General anaesthesia · Drug: Multimodal analgesia and antiemetic prophylaxis

Interventions

  • DrugIntrathecal bupivacaine, morphine and atropine

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hyperbaric bupivacaine 10 mg + preservative-free morphine 100 µg + atropine sulphate 100 µg in 4 mL, single intrathecal injection before induction

  • ProcedureGeneral anaesthesia

    Lidocaine, fentanyl, propofol, rocuronium induction; sevoflurane maintenance; neostigmine-atropine reversal

  • DrugMultimodal analgesia and antiemetic prophylaxis

    Paracetamol 1 g and ketorolac 30 mg IV at skin closure; ondansetron 4 mg IV at end of anaesthesia

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative nausea and vomiting (PONV)

    Proportion of participants with a score of 1 or more on a 5-point PONV analogue visual scale (0 = none; 1 = nausea \<10 min or one vomit, no treatment; 2 = nausea \>10 min or two vomits, no treatment; 3 = nausea \>10 min or more than two vomits requiring treatment; 4 = refractory to treatment), assessed at 1 h in recovery and at 2, 6, 12 and 24 h on the ward. Higher scores indicate worse outcome.

    Time frame: Within 24 hours after surgery

Secondary outcomes

  1. Postoperative pain intensity

    11-point Numeric Rating Scale, 0 = no pain to 10 = worst imaginable pain; higher = worse.

    Time frame: 2, 6, 12 and 24 hours after surgery

  2. Number of participants requiring rescue morphine

    morphine 2 mg IV given for NRS greater than 6.

    Time frame: Within 24 hours

  3. Number of participants requiring rescue ondansetron

    ondansetron 4 mg IV given for PONV score of 3 or more.

    Time frame: Within 24 hours

  4. Total post-induction fentanyl dose

    Total post-induction fentanyl dose

    Time frame: Intraoperative period, from induction to end of anaesthesia

  5. Mean arterial pressure

    mmHg, non-invasive.

    Time frame: Pre-induction, after spinal injection, at and after insufflation, after desufflation, after extubation (intraoperative period)

  6. Heart rate

    beats per minute

    Time frame: Pre-induction, after spinal injection, at and after insufflation, after desufflation, after extubation (intraoperative period)

  7. Number of participants requiring vasopressor support

    Time frame: Intraoperative period

  8. Number of participants with heart rate below 50 beats/min

    as a safety measure for the intrathecal atropine.

    Time frame: intraoperative

07

Study locations

1 site
  • Cipto Mangunkusumo National Central General Hospital (RSCM)
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The informed consent obtained from participants and the ethics approval for this study provided for research data to be kept confidential, with access limited to regulatory authorities for verification purposes, and did not include provision for sharing individual-level data with third parties.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Mar 2026, 1 month.

Of 68 non-industry phase 4 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 68 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 1, 2026
StartActual
Feb 2, 2026
Primary completionActual
Mar 26, 2026
CompletionActual
Mar 26, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851870
Lead sponsor
Universitas Indonesia
Collaborators
Fakultas Kedokteran Universitas Indonesia
Responsible party
Pryambodho Pryambodho (Principal Investigator, Universitas Indonesia) — Principal investigator
First posted
Oct 1, 2026
Start date
Feb 2, 2026
Primary completion
Mar 26, 2026
Completion
Mar 26, 2026
Last update
Oct 1, 2026

Study contacts

Pryambodho Pryambodho, MD
principal investigator · Department of Anesthesiology and Intensive Care, FKUI-RSCM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Morphine · Atropine

Start the discussion